Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations

CNS Drugs(2025)10.1007/s40263-025-01217-0Source: DataRank Database

Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations is a research paper published in CNS Drugs (2025). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

gen nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 5.10)OA: hybridTopics (21)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Kellen H. Quigg ORCID,Stephen A. Goutman ORCID,Suzanne Quigley

Live enrichment

PubMed:40897992 PMC:PMC12423166 OpenAlex:https://openalex.org/W4413914123

National Institutes of Health

Grant: R01NS120926

National Institutes of Health

Grant: R01NS127188

Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry

Grant: R01TS000344

Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry

Grant: R01TS000327

James and Margaret Hiller and Linda and Eric Novak

FWCI

5.10

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: cc-by-nc

journalhttps://link.springer.com/content/pdf/10.1007/s40263-025-01217-0.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40263-025-01217-0.pdf

publisherhttps://link.springer.com/article/10.1007/s40263-025-01217-0/fulltext.html

journalhttps://doi.org/10.1007/s40263-025-01217-0

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40897992

Fields of Study

Amyotrophic Lateral Sclerosis ResearchNeurogenetic and Muscular Disorders ResearchParkinson's Disease Mechanisms and Treatments

MeSH Terms

Amyotrophic Lateral SclerosisAnimalsClinical Trials as TopicDNA-Binding ProteinsHumans

Keywords

Amyotrophic lateral sclerosisMedicinePsychopharmacologyNeurologyClinical trialRiluzoleIntensive care medicineNeuroscienceMultiple sclerosisPsychiatryPsychologyDiseasePathology

Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations

FAIR Checklist

Authors (3)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)